 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- CIVI 007 / CiVi Biopharma
Phase classification: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (clinicaltrials.gov) - Feb 13, 2025
P2, N=49, Completed, Sponsor: Civi Biopharma, Inc.
Phase classification: P2a --> P2
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Aurlumyn (iloprost intravenous) / CiVi Biopharma
Journal: Iloprost (Aurlumyn) for frostbite. (Pubmed Central) - Jul 15, 2024
Phase classification: P2a --> P2 No abstract available
- iloprost intravenous (CIVI030) / CiVi Biopharma
COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART () - May 29, 2024 - Abstract #EULAR2024EULAR_4076;
No abstract available PDUS examination of the PU and FP area can demonstrate an ILO chronic effect in SSc patients with long-lasting disease.
- iloprost intravenous (CIVI030) / CiVi Biopharma
SAFETY AND EFFICACY OF INTRAVENOUS ILOPROST IN THE TREATMENT AND PREVENTION OF SCLERODERMA-RELATED DIGITAL ULCERS (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_182;
Our data shows that i.v. IIoprost has proved to be safe and effective for treating and preventing ulcers in scleroderma. The correlation between CV risk factors and the worsening of DUs underlines the importance of managing these conditions, not just in terms of prevention, but also as an integral part of the course of treatment for vasculopathy in scleroderma.
- iloprost intravenous (CIVI030) / CiVi Biopharma
ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_175;
PDUS examination of the PU and FP area can demonstrate an ILO acute effect in SSc patients with long- lasting disease. Therapy with CCB and presence of HAP impact on PD score improvement.
- ||||| Aurlumyn (iloprost intravenous) / CiVi Biopharma
Trial completion: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Jul 14, 2021
P3, N=198, Completed, Sponsor: Eicos Sciences, Inc.
Therapy with CCB and presence of HAP impact on PD score improvement. Active, not recruiting --> Completed
- |||| Aurlumyn (iloprost intravenous) / CiVi Biopharma
Enrollment closed: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Mar 16, 2021
P3, N=180, Active, not recruiting, Sponsor: Eicos Sciences, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || CIVI 007 / CiVi Biopharma
Trial completion: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (clinicaltrials.gov) - Jan 26, 2021
P2a, N=49, Completed, Sponsor: Civi Biopharma, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche, iloprost intravenous (CIVI030) / CiVi Biopharma
Clinical, Journal: Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. (Pubmed Central) - Nov 12, 2020
• More than half of the patients with recurrent DU received bosentan and/or sildenafil. • However, the proportion of patients on combination therapy of more than one vasoactive/vasodilating drug was low and almost one out of four patients with current and recurrent DU was on CCBs alone.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, iloprost intravenous (CIVI030) / CiVi Biopharma
[VIRTUAL] Long-Term Tolerability of Aminaphtone in Raynaud's Phenomenon Secondary to Systemic Sclerosis () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2063;
Aminaphtone shows an acceptable long-term tolerability along with sustained efficacy in the management of SSc-related RP, without disabling side effects. A randomized controlled trial for Aminaphtone use in the management of SSc-related RP is desirable
- |||| Aurlumyn (iloprost intravenous) / CiVi Biopharma
Enrollment open: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Oct 4, 2020
P3, N=180, Recruiting, Sponsor: Eicos Sciences, Inc.
A randomized controlled trial for Aminaphtone use in the management of SSc-related RP is desirable Active, not recruiting --> Recruiting
- || CIVI 007 / CiVi Biopharma
Trial completion, Enrollment change, Trial primary completion date: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (clinicaltrials.gov) - Sep 21, 2020
P1, N=36, Completed, Sponsor: Civi Biopharma, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=68 --> 36 | Trial primary completion date: Jul 2020 --> Feb 2020
- |||| Aurlumyn (iloprost intravenous) / CiVi Biopharma
Enrollment closed, Trial completion date, Trial primary completion date: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Jul 26, 2020
P3, N=180, Active, not recruiting, Sponsor: Eicos Sciences, Inc.
Active, not recruiting --> Completed | N=68 --> 36 | Trial primary completion date: Jul 2020 --> Feb 2020 Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- || CIVI 007 / CiVi Biopharma
Trial completion date, Trial primary completion date: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (clinicaltrials.gov) - Jun 29, 2020
P1, N=68, Active, not recruiting, Sponsor: Civi Biopharma, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Jul 2020
- || Aurlumyn (iloprost intravenous) / CiVi Biopharma
Trial completion: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) (clinicaltrials.gov) - Jan 29, 2020
P2, N=41, Completed, Sponsor: Eicos Sciences, Inc.
Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Jul 2020 Active, not recruiting --> Completed
- | CIVI 007 / CiVi Biopharma
Enrollment closed: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (clinicaltrials.gov) - Jan 22, 2020
P2a, N=48, Active, not recruiting, Sponsor: Civi Biopharma, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || CIVI 007 / CiVi Biopharma
Enrollment open: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (clinicaltrials.gov) - Dec 23, 2019
P2a, N=48, Recruiting, Sponsor: Civi Biopharma, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Aurlumyn (iloprost intravenous) / CiVi Biopharma
Trial primary completion date: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Nov 25, 2019
P3, N=160, Recruiting, Sponsor: Eicos Sciences, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2020 --> Jun 2020
- || CIVI 007 / CiVi Biopharma
New P2a trial: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (clinicaltrials.gov) - Nov 15, 2019
P2a, N=48, Not yet recruiting, Sponsor: Civi Biopharma, Inc.
- | CIVI 007 / CiVi Biopharma
Enrollment closed, Trial completion date: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (clinicaltrials.gov) - Oct 16, 2019
P1, N=68, Active, not recruiting, Sponsor: Civi Biopharma, Inc.
Trial primary completion date: Mar 2020 --> Jun 2020 Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Apr 2020
- | Aurlumyn (iloprost intravenous) / CiVi Biopharma
Enrollment open: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Oct 15, 2019
P3, N=160, Recruiting, Sponsor: Eicos Sciences, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Apr 2020 Not yet recruiting --> Recruiting
- | Aurlumyn (iloprost intravenous) / CiVi Biopharma
New P3 trial: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - Jul 30, 2019
P3, N=160, Not yet recruiting, Sponsor: Eicos Sciences, Inc.
- | CIVI 007 / CiVi Biopharma
Trial primary completion date: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (clinicaltrials.gov) - Jul 26, 2019
P1, N=68, Recruiting, Sponsor: Civi Biopharma, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2019 --> Dec 2019
- | Aurlumyn (iloprost intravenous) / CiVi Biopharma
Enrollment closed, Trial primary completion date: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) (clinicaltrials.gov) - Jun 11, 2019
P2, N=40, Active, not recruiting, Sponsor: Eicos Sciences, Inc.
Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: May 2019 --> Aug 2019
- | Aurlumyn (iloprost intravenous) / CiVi Biopharma
New P2 trial: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) (clinicaltrials.gov) - Mar 7, 2019
P2, N=40, Recruiting, Sponsor: Eicos Sciences, Inc.
- | CIVI 007 / CiVi Biopharma
New P1 trial: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level (clinicaltrials.gov) - Feb 9, 2018
P1, N=68, Recruiting, Sponsor: Civi Biopharma, Inc.